

Sanofi  
Form 6-K  
September 14, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2012**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

**(Address of principal executive offices)**

## Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If ☒ Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In September 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

**Exhibit List**

| Exhibit No.  | Description  |
|--------------|--|
| Exhibit 99.1 | Press release dated September 12, 2012: FDA Approves Genzyme's AUBAGIO (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis              |
| Exhibit 99.2 | Press release dated September 4, 2012: Sanofi Launches Modified Dutch Auction Tender Offer to Purchase up to 86,766,040 of its Outstanding Contingent Value Rights |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 14, 2012

SANOFI

By /s/ John Felitti

Name: John Felitti

Title: Associate Vice President,

Corporate Law, Financial &

Securities Law

**Exhibit Index**

| Exhibit No.  | Description  |
|--------------|--|
| Exhibit 99.1 | Press release dated September 12, 2012: FDA Approves Genzyme's AUBAGIO (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis              |
| Exhibit 99.2 | Press release dated September 4, 2012: Sanofi Launches Modified Dutch Auction Tender Offer to Purchase up to 86,766,040 of its Outstanding Contingent Value Rights |